Search This Blog

Friday, October 30, 2026

AbbVie beats, raises full-year adjusted EPS guidance, boosts dividend

 

AbbVie beats Q3 2026 estimates with non-GAAP EPS $3.82 (+105% YoY) and revenue $17.4B (+10% YoY), raises full-year adjusted EPS guidance, boosts dividend 5.2%

  • AbbVie now expects full-year adjusted EPS guidance range of $13.95–$13.99 following Q3 2026 results.
  • Company confirms completion of Apogee Therapeutics acquisition alongside reporting its Q3 2026 financial results.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)